Ardelyx, Inc. (ARDX)

Market Cap	1.24B
Revenue (ttm)	159.11M
Net Income (ttm)	-65.81M
Shares Out	233.98M
EPS (ttm)	-0.29
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	22,498,343
Open	6.25
Previous Close	7.57
Day's Range	5.07 - 6.47
52-Week Range	3.16 - 10.13
Beta	0.78
Analysts	Strong Buy
Price Target	13.21 (+150.19%)
Earnings Date	Jul 31, 2024

About ARDX

Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation. It also develops XPHOZAH, which is in Phase III clinical trial to reduce serum phosphorus in adults with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia; RDX013, a potassium secretagogue, for the treatment of el...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jun 19, 2014
• Employees: 267
• Stock Exchange: NASDAQ
• Ticker Symbol: ARDX

Financial Performance

In 2023, Ardelyx's revenue was $124.46 million, an increase of 138.61% compared to the previous year's $52.16 million. Losses were -$66.07 million, -1.70% less than in 2022.

Analyst Forecast

According to 8 analysts, the average rating for ARDX stock is "Strong Buy." The 12-month stock price forecast is $13.21, which is an increase of 150.19% from the latest price.

Price Target

$13.21

(150.19% upside)

Analyst Consensus: Strong Buy